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BMI: 25 ± 4   kg.m2, mean ± SD) into a 4-day study, 
with DXA and consumption of  D2O and  D3-Cr trac-
ers on day 1.  D3-3MH was consumed on day 3, 24 h 
prior to returning to the lab. From urine, saliva and 
blood samples, and a single muscle biopsy (vastus 
lateralis), we determined muscle mass, MPS and 
MPB.  D3-Cr derived muscle mass was positively cor-
related to appendicular fat-free mass (AFFM) esti-
mated by DXA (r = 0.69, P = 0.027). Rates of cumu-
lative myofibrillar MPS over 3  days were 0.072%/h 
(95% CI, 0.064 to 0.081%/h). Whole-body MPB over 
6 h was 0.052 (95% CI, 0.038 to 0.067). These rates 
were similar to previous literature. We demonstrate 
the potential for  D3-Cr to be used alongside  D2O 
and  D3-3MH for concurrent measurement of muscle 
mass, MPS, and MPB using a minimally invasive 
design, applicable for clinical and frail populations.
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Introduction
Skeletal muscle is the largest organ of the body by 
mass, accounting for 30–50% of whole-body total 
protein turnover [1–3]. It contributes to approxi-
mately 60% of basal metabolic rate [4]. Loss of 
muscle mass and function (sarcopenia) is linked to 
ill-health and clinical outcomes in ageing, and con-
ditions such as diabetes and cachexia [5, 6]. Skeletal 
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Abstract Optimising approaches for measuring 
skeletal muscle mass and turnover that are widely 
applicable, minimally invasive and cost effective 
is crucial in furthering research into sarcopenia 
and cachexia. Traditional approaches for measure-
ment of muscle protein turnover require infusion of 
expensive, sterile, isotopically labelled tracers which 
limits the applicability of these approaches in cer-
tain populations (e.g. clinical, frail elderly). To con-
currently quantify skeletal muscle mass and muscle 
protein turnover i.e. muscle protein synthesis (MPS) 
and muscle protein breakdown (MPB), in elderly 
human volunteers using stable-isotope labelled trac-
ers i.e. Methyl-[D3]-creatine  (D3-Cr), deuterium 
oxide  (D2O), and Methyl-[D3]-3-methylhistidine 
 (D3-3MH), to measure muscle mass, MPS and MPB, 
respectively. We recruited 10 older males (71 ± 4 y, 
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muscle metabolism is responsive to anabolic inter-
ventions such as exercise, nutrition, and certain 
pharmaceuticals [7–9]. The three main, related, 
parameters of muscle metabolism are: muscle mass, 
muscle protein synthesis (MPS), and muscle protein 
breakdown (MPB). As such, measurement of all three 
aspects within a single protocol is desirable.
Muscle volume and, by inference, mass can be 
measured using DXA, MRI and CT [10]. These tech-
niques are minimally invasive; however, access to 
them for use can often be limited as they are costly, 
not readily accessible, and some (i.e. DXA and CT) 
expose the participant to ionising radiation [11]. DXA 
is the most ubiquitously employed imaging approach 
in skeletal muscle research, although it is subject to 
overestimation of muscle mass [12, 13]. This issue 
has led to the recent re-emergence of the stable iso-
tope labelled tracer creatine technique [12], using 
methyl-[D3]-creatine  (D3-Cr) to quantify whole-body 
skeletal muscle mass, as a minimally invasive, inex-
pensive, and accurate alternative to the aforemen-
tioned imaging approaches. Following ingestion of 
a known dose of  D3-Cr, the amount retained in the 
body can be determined from the quantification of 
the amount of labelled creatine that ‘spills over’ in 
a subsequent 24-h pooled urine sample. The ratio of 
labelled to unlabelled creatinine (which is derived 
from the conversion of creatine to creatinine in the 
total muscle pool [14]) in urine samples taken at 48 
and 72 h after ingestion of  D3-Cr is then determined, 
and from these measurements, the size of the whole 
body muscle creatine pool can be estimated [15]. 
A further simple calculation can then estimate total 
whole-body skeletal muscle mass, assuming that 
there is 4.3 g creatine per kg of muscle [12]. Using 
this approach, Clark et al. (2014) established a strong 
correlation (r = 0.868) with whole-body muscle mass 
assessement using MRI.
MPS in  vivo has traditionally been quantified 
using measures of uptake of stable isotopically 
labelled amino acids administered as an intravenous 
bolus or infusion [16–18], and this approach has been 
used experimentally to compare a baseline state (such 
as resting or fasted) with that after an intervention 
(e.g. feeding, exercise or a pharmacological agent) [9, 
19, 20]. However, the quantification of ‘free-living’, 
cumulative MPS using non-substrate specific deu-
terium  (D2O) tracing methods has recently emerged 
as an important advancement in the field. In these 
methods, deuterium is rapidly equilibrated in the 
body water pool (over 1–2 h), exchanges onto amino 
acids (such as alanine) through intermediary meta-
bolic pathways and is subsequently incorporated into 
protein [21]. Measurement of these processes permits 
the quantitation of cumulative MPS over varying time 
periods from hours or days [22] to weeks or months 
[9, 19]. As such, these approaches can be applied 
in free-living people outside of a laboratory, which 
facilitates their use in the study of, for example, nutri-
tion and physical (in)activity/exercise over clinically 
meaningful time periods.
The quantification of MPB is arguably more dif-
ficult than both muscle mass and MPS. Traditional 
in  vivo approaches include arterio-venous (A-V) 
balance and fractional breakdown methods [23, 24], 
quantifying the dilution of amino acid tracers across 
the A-V system of an isolated organ or limb follow-
ing the breakdown of tissue protein. These invasive 
approaches are reliant upon robust and regular blood 
sampling and/or blood flow measures, both of which 
have inherent limitations, such as the practicality of 
numerous and correctly timed blood samples [25]. 
Another approach has been to measure the concentra-
tion of 3-methylhistidine (3-MH) in urine. 3-MH is 
a post-translational modification of contractile pro-
tein histidine residues, which are not subject to re-
incorporation into nascent peptide synthesis, as there 
is no aminoacyl-tRNA for 3-MH [26]. However, this 
approach lost favour as urinary 3-MH levels may be 
perturbed by dietary meat intake [27] (an alternative 
source of 3-MH); and the assumption that methyl-
ated-histidine is exclusively derived from skeletal 
muscle of the appendicular skeleton may be incor-
rect, as the gut has also been shown to be a source 
of 3-MH [28]. Nevertheless, an adaptation of this 
approach using tracer dilution was reported recently 
in which 10 mg of stable isotopically labelled 3-meth-
ylhistidine (either  D3 or 13C) was administerd orally, 
and the rate of dilution of this tracer by endogenously 
released 3-MH was determined in plasma or urine 
over 6 h to assess the rate of whole-body myofibrillar 
protein breakdown [26]. This method offers a simple, 
attractive alternative which does not require accurate 
and complete 24-h urinary collection because a much 
more easily collected series of spot urine or plasma 
samples can be used.
To date, there has been no attempt to create a 
single protocol to streamline minimally invasive 
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techniques to simultaneously measure muscle protein 
turnover and muscle mass. Being able to do so would 
have considerable clinical research application in 
non-laboratory settings (i.e. in the community, hospi-
tals or care homes) and/or in patient groups who find 
it difficult to comply with, or understand, invasive 
approaches, such as frail individuals or those with 
disabilities. Therefore, the aim of this study was to 
develop a single combined oral stable isotope assess-
ment of muscle (which we term ‘COSIAM’) to con-
currently quantify skeletal muscle mass and muscle 
protein turnover; MPS and MPB, using stable isotope 
methods with  D3-Cr,  D2O and  D3-3MH, respectively.
Methods
Study protocol
This study was approved by The University of Not-
tingham Ethics Committee (A08122015) and con-
formed to the standards set by The Declaration of 
Helsinki (2013).
Ten healthy older males were recruited (71 ± 4y, 
BMI: 25 ± 4   kg.m2, mean ± SD). Before being 
enrolled into the study, all participants had a full 
medical screening. Height, weight, full medical his-
tory, blood pressure, an ECG and clinical chemistry 
(full blood count, urea and electrolytes, liver func-
tion tests, thyroid function tests and coagulation) 
were used to assess subject eligibility to participate 
in the study. Participants were excluded if they had a 
BMI > 35  kg·m2, active cardiovascular disease, cer-
ebrovascular disease, respiratory disease, metabolic 
disease, inflammatory bowel or renal disease, active 
malignancy, any musculoskeletal or neurological dis-
orders, any signs of clotting dysfunction, any recent 
steroid treatment (within 6 months), or if on hormone 
replacement therapy. All participants were informed 
of the purpose of the study and of all the risks and 
procedures involved, before providing their written, 
informed consent.
On the first study day (Day 1), participants were 
asked to attend the unit at 8:30 am for a whole-body 
DXA scan, having fasted overnight. They provided 
a baseline saliva sample (to identify baseline body 
water enrichment) and then performed the Short 
Physical Performance Battery Test (SPPBT). Leg 
extensor strength (single-leg 1RM and maximal 
voluntary contraction for leg extension) and hand-
grip strength (using Takei (T.K.K. 5401 GRIP-D) 
handgrip dynamometer) were also measured. A 
baseline 10 ml blood sample was taken to measure 
background blood/plasma alanine labelling prior to 
 D2O exposure. A baseline urine sample was col-
lected to measure  D3-creatinine enrichment. Par-
ticipants were then given three 50 ml aliquots of 70 
atom percent  D2O to drink, each taken 25 min apart 
to minimise the risk of side effects such as dizziness 
or nausea that are sometimes reported after  D2O 
consumption due to disturbance of specific gravity 
within the vestibular fluid [29]. 30  mg  D3-Cr was 
included in the final 50 ml aliquot of  D2O.
Two hours after consumption of the final  D2O 
aliquot, participants provided another saliva sample, 
to be used to determine the plateau  D2O concentra-
tion in body water.
Prior to leaving the laboratory, participants 
were provided with a container to collect all urine 
for 24 h, a tube for a spot urine sample at 48 h and 
three tubes for saliva samples at 12, 24 and 48  h 
after the final  D2O aliquot was consumed. These 
samples were used to measure  D3-creatine spill-
over, urinary  D3-creatinine enrichment and the size 
of the creatine pool, respectively. Participants were 
also given 10  mg of  D3-3MH dissolved in 50  mL 
of water to take home and store refrigerated. Par-
ticipants were instructed to consume the  D3-3MH 
immediately after the 48-h samples were collected 
(Fig.  1). Please refer to Fig.  1  for an illustrative 
depiction of the COSIAM approach.
Participants returned to the laboratory 72 h after 
consumption of the final  D2O aliquot given on the 
first study visit, again having fasted overnight. At 
this visit, hourly bloods were collected over 6  h 
(between 72 and 78 h after consumption of the final 
 D2O aliquot), plus a further spot urine and saliva 
sample at 72 h. A muscle biopsy from the m. vastus 
lateralis (VL) was also taken at this visit (at 72 h) 
under local anaesthetic (1% lidocaine). The Bard 
micro-needle biopsy technique (50% length of VL, 
mid-belly) was used for the first 5 participants, with 
the conchotome approach [30] used subsequently 
to achieve a larger tissue yield for further analyses. 
Participants were not fasted throughout the blood 
sampling period, with a standardised light meal 
 GeroScience
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Fig. 1  Schematic representation of the combined use of  D3-3MH,  D2O and  D3-Cr to measure myofibrillar muscle protein synthesis 
(MPS) (A), whole-body muscle protein breakdown (MPB) (B), and muscle mass (C), simultaneously
Fig. 2  Study schematic
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(sandwich, crisps, yoghurt and drink) provided at 
the midpoint of the blood collections for all partici-
pants. Figure 2 illustrates the protocol.
Sample analysis
Measurement of body water enrichment in saliva, 
for the estimation of alanine precursor enrichment
One hundred microlitres of each saliva was ali-
quoted into the cap of auto-sampler vials which were 
crimped onto inverted vials and placed on a heating 
block at 90 °C for 4 h. These vials were then immedi-
ately cooled upright on ice for 10 min and the water 
collected transferred to fresh vials. The samples were 
then injected into a high temperature conversion ele-
mental analyser (TC/EA; Thermo Scientific, Hemel 
Hempstead, UK) connected to an Isotope Ratio Mass 
Spectrometer (IRMS; Delta V Advantage, Thermo 
Scientific) [20]. The mean of the final 3 of 4 repeat 
injections was taken to control for carry over from 
previous samples. The mean area under the curve 
(AUC) of the atom percent excess (APE) was used 
to represent the average precursor labelling of free 
intramuscular alanine, multiplied by 3.7 to account 
for deuterium exchange into alanine from  D2O, for 
the determination of muscle fractional synthetic rate 
(FSR).
Preparation of muscle for measurement 
of incorporation of deuterated alanine, for MPS 
determination
Between 30 and 50  mg of muscle was used for the 
analysis of deuterium labelling of alanine in the myofi-
brillar protein bound fraction, although 10 mg is suffi-
cient, thereby permitting the needle biopsy approach. 
The muscle tissue was homogenised with scissors 
in an Eppendorf tube using 10 μL/mg−1 of ice-cold 
homogenisation buffer (50  mmol Tris–HCl, 1  mmol 
EDTA, 1 mmol EGTA, 10 mmol β-Glycerophosphate, 
50 mmol NaF, 0.5 mmol of activated sodium orthova-
nadate, pH 7.4 (all from Sigma Aldrich, Poole, UK) 
containing a complete protease inhibitor cocktail tab-
let (Roche, West Sussex, UK). The homogenate was 
mixed at 1000 rpm for 10 min before being centrifuged 
at 10,000 × g for 10 min at 4 °C. The supernatant (sar-
coplasmic fraction) was then collected and the pellet 
was resuspended in 500 μL mitochondrial extraction 
buffer (MEB) and then homogenized by Dounce and 
centrifuged at 1000 g for 5 min. The myofibrillar pel-
let was solubilised using 1  mL 0.3  molL−1 NaOH 
and incubated for 30  min at 37  °C, then centrifuged 
for 10 min, at 4 °C and 10,000 rpm. The myofibrillar 
fraction (supernatant) was separated from the insolu-
ble collagen pellet, and precipitated by the addition of 
1  mL 1  molL−1 perchloric acid, following incubation 
at 4  °C for 20 min. The myofibrillar protein was pel-
leted at 4000 rpm for 20 min, separated from the super-
natant containing the free amino acids, then washed 
twice with 70% ethanol. After the addition of 1 mL 0.1 
 molL−1 HCl and 1 mL of a Dowex  H+ resin slurry, the 
samples were incubated overnight at 110  °C in order 
to release the protein-bound amino acids [20, 31, 32]. 
The plasma was deproteinised using ice-cold ethanol 
(100%) and centrifuged at 17,000  g for 10  min. The 
pellet was transferred to a boiling tube containing on 
dowex with 0.1  M HCl and hydrolysed, overnight at 
110 °C 16–20 h; following the same preparation steps 
as the muscle sample.
The amino acids (AA) were derivatized as their 
N-methoxycarbonyl methyl esters (MCME) as pre-
viously described [33]. Briefly, the AA were re-sus-
pended in 60 μL of distilled  H2O and vortex mixed 
before the addition of 32 μL of methanol and 10 μL 
of pyridine. 8 μL of methylchloroformate (MCF) was 
carefully added directly into the aqueous mix and 
immediately vortex mixed for 30  s. The solution was 
left at room temperature for 5 min to react. Following 
the addition of 100 μL of chloroform and 100 μL of 
0.001  M  NaHCO3, the samples were vortexed mixed 
to extract the MCME amino acids. Molecular sieve was 
added to remove any excess water from the sample. The 
sample was transferred to an autosampler vial, ready 
for mass spectrometric analysis. Deuterium enrich-
ment into protein-bound alanine was measured using 
gas-chromatography-pyrolysis-isotope-ratio-mass spec-
trometry (GC-pyrolysis-IRMS, Delta V Advantage, 
Thermo Scientific) [34].
The calculation of myofibrillar fractional synthetic 














where  APEAla is deuterium enrichment of protein-
bound alanine,  APEP is mean alanine enrichment cor-
rected from  D2O, and t is the time between the plasma 
sample to the 72  h muscle biopsy, using previously 
described equations [19].
Measurement of D3‑3‑methyl‑histidine in blood, 
for MPB determination
Blood was taken, then centrifuged at (3200  rpm, 
20 min, 4 °C), the plasma aliquoted into eppendorfs 
and stored at − 80 °C. Plasma samples were defrosted 
and centrifuged at ~ 10,000 rpm for 3 min. A 0–10% 
 D3-3-methyl-histidine enrichment curve was prepared 
as a serial dilution. 100 µL of plasma was de-protein-
ised using 1  mL of MeCN: MeOH (1:1). Samples 
were vortex mixed and incubated at − 20 °C for 1 h. 
Samples were centrifuged at ~ 13,000  rpm for 5 min 
at 4 °C. The supernatant was dried down in a Techne 
Block at < 40  °C using nitrogen gas. Samples were 
re-suspended using 100 µL MeCN:  ddH2O (65:35) 
and ready to be analysed using High-Performance 
Liquid Chromatography (HPLC; Dionex Ultimate 
3000, Thermo Scientific) mass spectrometry (MS; 
Q-Exactive, Thermo Scientific) with a Sequant ZIC-
HILIC column (150  mm × 2.1 × 5um; Merck Milli-
pore). The flow was set to 0.4 mL/min with an initial 
buffer gradient of 95:5 (Buffer A:B); where Buffer 
A was 10  mM ammonium formate (90:10 Acetoni-
trile:  ddH2O) with 0.1% Formic Acid and Buffer B 
was 10 mM ammonium formate (50:50 Acetonitrile: 
 ddH2O) with 0.1% Formic acid. After a 2.5-min 
hold at 95:5 (A:B), the buffer gradient was ramped 
to 100% Buffer B over 15 min and held for 2.5 min 
before returning back to 95:5 (A:B) and re-equil-
ibrated for 10  min. Accurate mass single ion moni-
toring was performed for  M+H (mass + hydrogen 
cation): 170.09230 (3MH) and 173.11131  (D3-3MH) 
to determine enrichment of  D3-3MH. The enrichment 
ratios were log transformed to determine the decay 
rates (k), representative of the rate of whole-body 
MPB [26].
Determination of creatine spillover and creatinine 
enrichment in urine samples for calculation of whole 
body muscle mass
The urine samples were prepared using a method 
based on that described by Leonard et al. [35]. Sam-
ples were freeze-thawed (1 ×) at room temperature 
and vortex mixed, before 10 µL of 13C-Creatine 
(20 µg/mL) was added to 50 µL of urine, as an internal 
standard. 250 µL of ice-cold acetonitrile was added 
both samples and standards, vortex mixed and cooled 
on ice for 30 min. Samples were then centrifuged at 
17,000  g for 20  min. The supernatant was filtered 
through a 0.2 µm filter and transferred to vials ready 
for HPLC–MS analysis using the same instrumenta-
tion and column as above [35]. The flow was set to 
0.2 mL/min, 60:40 (Buffer A:B) isocratic flow; where 
Buffer A was 100% Acetonitrile and Buffer B Ammo-
nium Acetate pH 5.8. A standard curve using 12C, 13C 
and  D3-Creatine was prepared for the determination 
of creatine concentration and enrichment (monitoring 
M + H: 132.07666, 133.08006 and 135.09549 respec-
tively), with a  D3-creatinine enrichment curve of 
0–0.1% for determination of  D3 − creatinine enrich-
ment (monitoring M + H: 114.06638 and 117.08515). 
Fig. 3  A Deuterium enrich-
ment of the body water, 
measured in APE from 
saliva samples at baseline, 
2, 12, 24, 48 and 72 h post-
deuterium oxide ingestion; 
(B) Myofibrillar fractional 
synthetic rates. n = 10 older 
males. Mean and 95% CI 
presented










































From the measurement of urinary  D3 − creatine in the 
24-h urine (spillover) and  D3 − creatinine enrichment 
in the 48 h and 72 h spot urines, total creatine pool 
size and therefore total whole body muscle could be 
calculated using the following equation:
where MWUnlabelled and MWlabelled represent the 
molecular weights of both unlabelled (131.1) and 
labelled creatine (134.1), respectively. The estimated 
creatine pool size is then divided by 4.3 g/kg which 
reflects the average concentration of creatine found in 
whole wet muscle tissue [12].
Statistical analyses
As the methods have individually been previously 
validated, here we aimed to measure rates of MPS 
and MPB using our COSIAM approach, to identify 
if values obtained were similar to previous literature. 
Furthermore, we aimed to confirm if there was a rela-
tionship between DXA and  D3-creatine-derived esti-
mates of muscle mass. All data sets were tested for 
normality using Shapiro–Wilk test with alpha set at 
0.05. Linear regression and two-tailed Pearson r cor-
relation analysis were used to identify any relation-
ship between muscle mass estimates by  D3-creatine 
and DXA, with confidence interval set at 95%. All 
statistical analysis was performed using Graphpad 
Prism software (Prism 8, USA).
Results
Myofibrillar protein synthesis and body water 
enrichment
The mean body water enrichment of  D2O peaked at 2 h 
(0.24 APE; 95% CI, 0.23 to 0.26 APE) and then declined 
slowly over 72 h to 0.18 APE (95% CI, 0.16 to 0.20 APE; 
Fig. 3A). The mean myofibrillar FSR over 0–72 h was 
0.072%/h (95% CI, 0.064 to 0.081%/h; Fig. 3B).
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Determination of rates of muscle protein breakdown 
(MPB) by D3‑3‑methylhistidine dilution
The  D3-3MH enrichment curve of 0–10 APE 
(Fig.  4A) showed good linearity, whereby APE 
measured at different enrichments were identi-
cal to the expected APE (slope = 1.060). Mean 
plasma  D3-3-MH enrichment gradually declined 
from 4.86 ± 2.25 APE at 24  h post-tracer ingestion 
to 3.65 ± 1.82 APE at 30  h (Fig.  4B). The ratio of 
labelled to unlabelled 3-MH was log transformed to 
determine the rate of whole-body MPB. The gradi-
ent of the straight line provides the k value (rate con-
stant). The mean rate of whole-body MPB was 0.052 
(95% CI, 0.038 to 0.067; Fig. 4C).
Determination of muscle mass using D3‑Creatine
This analytical approach was extremely sensitive, accu-
rate and robust, and both standard curves showed good 
linearity across both the range of concentrations of cre-
atine expected (i.e. 0.25 to 5 µg; Fig. 5A) and expected 
 D3-Cr enrichments (i.e. 0–0.1APE; Fig.  5B). In our 
hands, only very small amounts of  D3-Cr were excreted 
during the 0–24 h collection period (0.38% of the initial 
dose; Fig.  6B).  D3-Cr enrichment in the urine samples 
increased over time and plateaued at 48 h, there was no 
significant difference between 48 and 72 h enrichments 
(Fig. 6C); as such, the mean enrichment values of the 48 h 
and 72 h urine samples were then used to calculate mus-
cle mass. There was no significant correlation between 
DXA-derived FFM and muscle mass measured by  D3-Cr 
(r = 0.55, p = 0.098). However, DXA-derived AFFM 
was significantly positively correlated with muscle mass 
measured by  D3-Cr (r = 0.69, p = 0.027; Fig. 6D).
Discussion
We present a minimally invasive study designed 
to measure rates of MPS, MPB and muscle mass 
concurrently, using a novel combination of orally 





























































































Fig. 4  A Enrichment curve of  D3-3-methylhistidine from 
0–10 APE; (B) Decay curves of  D3-3-methylhistidine in 
the plasma by endogenous 3-methylhistidine release; (C) 
Rate of whole-body muscle protein breakdown (k) using 
 D3-3-methylhistidine. n = 10 older males. Mean and 95% CI 
presented






































Fig. 5  A Creatine concentration curve ranging from 0.25–5  µg of creatine where M0 is creatine and M1 is 13C-creatine; (B) 
 D3-creatinine enrichment curve ranging from 0 to 0.1 APE for measured vs. expected APE
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spectrometric measures made in saliva, and blood 
or urine samples, in conjunction with a single mus-
cle biopsy. In contrast to traditional stable isotope 
approaches using intravenous tracer infusions, which 
require extremely well-controlled laboratory condi-
tions and imaging techniques, our protocol has the 
potential to be applied to a wider range of cohorts and 
settings.
In our protocol, we used a creatine tracer method 
to quantify muscle mass. The use of 30  mg  D3-Cr 
tracer was based upon the dosing validation by 
Clark and colleagues in 2014 where 30  mg was 
identified as adequate for quantification of muscle 
mass, a finding that we support. Our results also 
corroborate previous relationships between DXA-
derived parameters of skeletal muscle and muscle 
mass measured using  D3-creatine [12, 36, 37]. A 
significant correlation was only found between mus-
cle mass measured by  D3-creatine and AFFM calcu-
lated from DXA (and not with FFM by DXA), this 
may be due to the fact that DXA does not measure 
muscle mass directly. Our findings are supported by 
those of Proctor et  al., who found the strength of 
relationship between a urinary creatinine excretion 




































































































Fig. 6  A Corrected ratio of  D3-Creatine/Creatine excreted in 
the urine for samples collected at Baseline (0 h), 24 h (pool), 
48 and 72  h (spot); (B) Percentage dose not absorbed by the 
body in 0–24 h urine collection sample. Values displayed are 
min to max; (C) Ratio of labelled creatinine  (D3-creatinine) 
to unlabelled creatinine, corrected to the baseline sample 
(0 h) for 24, 48 and 72 h urine samples. Values displayed are 
mean ± 95% CI; (D) Correlation between muscle mass meas-
ured by  D3-Creatine method with fat free mass (FFM) and 
appendicular fat free mass (AFFM i.e. total arms and legs) 
measured by DXA. Values displayed are mean ± 95% CI
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method and DXA for assessing FFM declined with 
age [38]. In addition, FFM as measured by DXA is 
considerably higher (~ 60%) than the muscle mass 
determined using  D3-creatine. Therefore, if DXA 
FFM is used to determine muscle mass, it will pro-
vide an erroneous overestimation of total muscle 
[and by extenstion, contractile] mass [39]. Ideally, 
the gold-standard approach to determine muscle 
mass (i.e., MRI) would have been used for compari-
son, however, a very close correlation between MRI 
and  D3-creatine has been previously documented 
[12]. Although there is a strong correlation between 
AFFM using DXA or MRI, and muscle mass meas-
ured by  D3-creatine, a potential limitation that 
requires further validation, is the widespread use of 
the 4.3 g creatine per kg muscle constant to calcu-
late muscle mass based upon the size of the creatine 
pool [12]. It is important to ensure that the constant 
used accurately reflects intramuscular creatine in 
different populations, particularly where the mus-
cle creatine pool size may vary e.g. vegetarians 
[40], athletes, especially following acute or endur-
ance exercise [41] or when creatine is being sup-
plemented in the diet [42]. When considering the 
impact of dietary intake, although a large amount 
of creatine can be found in meat, average inges-
tion is ~ 1  g/day [43] in an omnivorous diet. In an 
average 70 kg young male the creatine pool size is 
approximately 120–140 g [43] with creatine excre-
tion approximately 1.7%/day [44] as such aver-
age meat ingestion should not affect this measure; 
indeed significant changes in creatine pool size 
(~ 20%) have only been observed when supplemen-
tating creatine of 20 g/day over 6 days [45].
Given the precision of the  D3-Cr measurement in 
our hands, we calculate it would be possible to detect 
a change in muscle mass of 1 kg, equal to ~ 0.03 APE, 
and therefore has the sensitivity to identify clinically 
meaningful changes [46]. Future applications of this 
approach could also look to minimise the urine sam-
pling to a single spot urine, given that the spillover 
is less than 0.4% in our participants, perhaps due to 
the lower dose given, and this would lead to < 0.4% 
error in muscle mass calculation. We speculate that 
the percentage spillover may be related to the cre-
atine pool size and thus, muscle mass and should be 
investigated further. Going forward, we suggest that 
1 or 2 spot urine samples taken 48–72 h after inges-
tion of tracer would suffice, making the method even 
more practicable and widely applicable. To exem-
plify, in this data set, removing the correction of the 
24 h collection, led to an average increase in muscle 
mass estimation of 9 g. Alternatively, Shankaran et al. 
(2018), developed an algorithm to correct for  D3-Cr 
spillage based on a relationship identified between 
fasting creatine:creatinine ratio and  D3-Cr dose 
excreted from a urine sample, thereby, removing the 
need for the 24 h pooled collection [47].
Using  D2O to study skeletal muscle protein metab-
olism is now a well-established stable-isotope tracer 
technique that has been validated for both longer 
(over weeks or months; [19]) and also relatively short 
study durations i.e. over 2–8 days [22], and even over 
as little as 3 h with appropriate increases in the pre-
loading dose [20]. For instance, as little as 150  mL 
(70 AP)  D2O) was adequate to measure MPS over 
2–8 days [22]; therefore, we used this dose to meas-
ure MPS in this 4-day protocol. In doing so, we report 
similar cumulative MPS values to those reported 
before [22, 48] and interference with the other co-
consumed tracers  D3-Cr or  D3-3MH (i.e.  D2O con-
taminating creatine/methylhistidine labelling) is 
negligble. It is unlikely that a deuterium labelling of 
either arginine or glycine (amino acids involved in the 
initial step of creatine biosynthesis) from  D2O would 
be incorporated to any extent into  D3-labelled guani-
dinoacetate (a precursor to creatine), given the very 
small dose of  D2O we use in this study, and therefore 
the probability of  D2O labelling all three position of 
the methyl group at this level of dosing is vanishingly 
small. In addition, it is possible to provide an alterna-
tively labelled tracer such as 13C-Cr for repeat meas-
urements, and this would be recommended in short 
duration longitudinal studies to avoid any overlap of 
isotopes given the slow turnover of these pools [22].
For measurement of whole-body MPB, 10  mg 
of  D3-3MH was utilised, as previously described by 
Sheffield-Moore and colleagues, with the rates of 
MPB in our older men similar to those previously 
observed (i.e. the rate constant (k) of approximately 
0.08, [26]). Sheffield-Moore et  al. (2014), reported 
no significant difference between the use of meat or 
meatless diets in their study and therefore diet was 
not controlled for in our study. It is important to note 
that subjects were not maintained fasted throughout 
the period of plasma sampling for  D3-3MH measures, 
therefore the rates of MPB we observed reflect the 
changes in MPB over the period of sampling. Feeding 
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increases insulin secretion which is known to inhibit 
MPB [49]; therefore, it is likely that our measures 
will somewhat reflect MPB in the fed state, thereby 
explaining why our MPB rates are slightly lower than 
the cummulative rates of MPS obtained in this study. 
One subject had a much lower  D3-3MH enrichment 
than the other subjects, which is probably indicative 
that they did not ingest the full 10  mg or perhaps 
took the dose much earlier than reported i.e. not the 
morning before; however, the decay rate determined 
was similar to that of our other participants, due to 
the high sensitivity and reproducibility of the LC–MS 
approach employed. Further investigations could look 
to reduce the dose of  D3-3MH given or standardise 
the dose on a weight or LBM basis to standardise 
the approach and measurement of enrichment across 
participants. Furthermore, using timed urine sam-
ples, instead of blood samples for the measurement 
of labelled  D3-3MH excretion could further minimise 
the invasiveness of this approach [26].
Other considerations to the work presented herein 
are warranted. With regard to selecting which time-
point to take the spot samples, Clark et  al. (2014) 
reported that a steady-state of  D3-creatinine enrich-
ment was achieved by 30.7 ± 11.2 h post-tracer inges-
tion and remained steady for a further 5  days [12]. 
As such, a single spot urine sample taken at any 
timepoint during this steady-state period (2–4  days 
post-ingestion of tracer) would be sufficient. For 
more acute measures, the timepoint for MPS meas-
urement could be altered i.e. shortened, and with an 
additional biopsy to measure MPS, with appropri-
ate sampling over the same time frame (i.e. 6  h) as 
MPB [20], also permitting us to adopt this approach 
pre- and post- longer term interventions. Although 
this would require additional biopsies, the use of the 
micro-needle biopsy technique [50], which is well 
tolerated [50], may be used towards developing a less 
invasive approach. It would also be possible to further 
shorten the time-frame and burden of these meas-
ures by providing all three tracers together on Day 0, 
obtaining plasma/urine samples the next day for MPB 
and a muscle biopsy at 24 h for MPS, and a spot urine 
at 48  h or 72  h post-tracer consumption for muscle 
mass estimation. Additionally, future adaptations 
to the COSIAM approach may include the replace-
ment of the muscle biopsy for the measurement of 
MPS with the use of the “virtual biopsy” approach 
to measure deuterium labelled plasma surrogates 
of MPS such as creatine kinase M-type (CK-M) or 
carbonic anhydrase 3 [51]. While this would further 
reduce the invasiveness of the approach and should 
be investigated further, the higher dose of deuterium 
oxide required for this approach may have a greater 
burden with the potential of increased side effects 
e.g. nausea. Furthermore, the relationship of plasma 
surrogates such as CK-M would require validation 
across different populations and scenarios. Finally, 
we speculate that where there is rapid muscle catab-
olism, such as in sepsis/burns, this approach would 
be equally valid for quantifying such gross perturba-
tions in proteostasis (in fact one may speculate larger 
effect sizes would be easier to detect). Nonetheless, 
oral tracing of  D3-3MH/D3- Cr does require gut/renal 
function and thus would need to be validated in rela-
tion to mapping the fate of oral tracers in populations 
of potential concern.
This study has demonstrated the feasibility of con-
current assessment of muscle protein turnover (i.e. 
MPS and MPB), and muscle mass through a far less 
invasive approach than using traditional stable iso-
tope infusion approaches. The COSIAM approach 
provides rates of protein turnover and estimates of 
muscle mass that are in agreement with previous indi-
vidual tracer approaches. The combination of these 
tracers via a minimally invasive approach has wider 
applicability than traditional methods and potential 
utility to provide novel, valuable information about 
the regulation of muscle mass in difficult to study 
clinical populations.
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